University of Kansas
Latest From University of Kansas
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
The California biotech proves that an early-stage company can be just as attractive to investors as a proof-of-concept biotech if the science is strong.
Financings Of The Fortnight: Overseas Cash Holdings Don’t Mean U.S. Biopharma Lacks For Domestic Financial Opportunity
Plus news on recent financing activity by Savara Pharmaceuticals, OvaScience, TetraPhase Pharmaceuticals and Pharmacyclics.
Savara Pharmaceuticals will finance an 80-patient Phase II trial for its inhaled vancomycin candidate as a treatment for MRSA infections in cystic fibrosis patients. Such infections have been linked with a six-year reduction in life expectancy.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.